I mmunoglobulin G4-related disease (IgG4-RD) is a newly established chronic inflammatory disorder characterized by massive infiltration of IgG4-expressing plasma cells into mul-tiple organs, elevated serum IgG4 levels, and storiform fibrosis (1, 2) . Various inflammatory disorders, such as those formerly diagnosed as autoimmune pancreatitis (AIP), sialadenitis, and autoimmune cholangitis, are now regarded as organ-specific manifestations of systemic IgG4-RD (1) (2) (3) (4) . Although elevated serum IgG4 levels define the presence of IgG4-RD-associated inflammation in a variety of organs, and thus it is essential for disease diagnosis, the pathophysiological role of this elevated Ig subtype is poorly understood. On one hand, elevated IgG4 levels may be an epiphenomenon associated with IgG4-RD-associated chronic inflammation, because this IgG subtype exhibits limited ability to bind to complement and FcgRs (5, 6) and has been shown to have anti-inflammatory activity in experimental myasthenia gravis (7) . On the other hand, enhanced IgG4 levels may play a vital immunopathologic role in this disease, because IgG4 Abs against autoantigens have also been shown to participate in the pathogenesis of autoimmunity (8, 9) .
Adaptive immune responses involving T cell-derived cytokines such as IL-4, IL-10, and IL-13 that have been found to promote IgG4 production by B cells (5, 10, 11) may be involved in IgG4-RDassociated IgG4 production, because the number of Th2 cells and regulatory T cells (Tregs) producing these cytokines are increased in IgG4-RD patient lesions and peripheral blood (12) (13) (14) . However, innate immune responses that activate B cells in a T cell-independent manner to induce Ig production upon exposure to microbialassociated molecular patterns (MAMPs) and damage-associated molecular patterns (15) may also be involved in the enhanced IgG4 production. This possibility is suggested by our previous studies in which we reported that TLR and nucleotide-binding oligomerization domain-like receptor activation in monocytes (16) and basophils (17) from patients with IgG4-RD enhance IgG4 production by B cells from healthy control individuals via production of BAFF.
Plasmacytoid dendritic cells (pDCs) are another potential source of BAFF in IgG4-RD, because these cells produce IFN-a, a cytokine known to enhance BAFF production (18, 19) . The involvement of pDCs in IgG4-RD immunopathogenesis aligns with the fact that pDC activation leading to increased IFN-a production has been postulated to be a major mechanism of autoantibody production in systemic lupus erythematosus (SLE). In this disease, FcR-mediated endocytosis of DNA/RNA-containing immune complexes are thought to activate pDCs expressing TLR7 and TLR9 and the pDCs so activated then induce autoantibodies (20, 21) . However, little is known regarding the potential involvement of pDC-mediated IFN-a production in IgG4-RD development.
In the current study, we show that increased number of pDCs producing IFN-a populate the inflamed pancreas in both the murine model of AIP and patients with IgG4-related AIP. In the murine model, we demonstrate by pDC depletion and IFN-a receptor blocking that these cells are a major cause of the pancreatitis. Furthermore, in both the murine model and humans with IgG4-related AIP, the inflamed pancreas contained neutrophil extracellular traps (NETs) that could be shown to activate pDCs from patients with IgG4-related AIP to produce IFN-a and BAFF, which leads to production of IgG4 by B cells. Overall, these data provide strong evidence that pDC activation and IFN-a production are prominent features of IgG4related AIP.
Materials and Methods

Induction of AIP in MRL /Mp mice
Female MRL/Mp mice were purchased from Japan SLC (Shizuoka, Japan). All mice were bred at Kyoto University animal facility under specific pathogen-free conditions. This study was approved by the Kyoto University ethics review boards for animal experiments. Six-week-old female MRL/Mp mice were treated by i.p. injections with 100 mg polyinosinic-polycytidylic acid [poly (I:C); InvivoGen, San Diego, CA] twice a week for a total of 14 or 16 injections to induce experimental AIP (22, 23) . In some experiments, mice were treated with Ab against bone marrow stromal cell Ag 2 (100 mg, 120G8; Bioceros, Utrecht, the Netherlands) and Ab against IFN-ab receptor (100 mg, anti-type I IFN receptor [IFNAR] Ab, MAR1-5A3; BD Biosciences, San Jose, CA) (24) prior to each poly (I:C) injection to deplete pDCs and inhibit type I IFN-mediated signaling pathways, respectively. Control mice were treated with either 100 mg rat IgG (Sigma-Aldrich, St. Louis, MO) or mouse IgG (Sigma-Aldrich).
Cytokine and chemokine array analysis
Pancreatic lysates were prepared as described previously (25) . Pancreatic lysates (100 mg) and serum (100 ml) were applied to a commercial membrane with bound mouse cytokine array panel A (R&D Systems, Minneapolis, MN) to screen for cytokine and chemokine profiles.
Flow cytometry analysis of the intrapancreatic immune cells
The pancreas was minced with scissors and shaken in RPMI 1640 buffer containing 10% FBS, 25 mmol/l HEPES, and 3 mg/ml collagenase (Wako, Osaka, Japan) at 37˚C and 180 rpm for 30 min. The cell suspension was spun at 50 3 g for 30 s to remove debris, followed by centrifugation with 30% Percoll solution (GE Healthcare, Tokyo, Japan) at 2000 rpm for 30 min at room temperature. Isolated pancreatic immune cells were stained with FITC, PE, or allophycocyanin-conjugated B220 Ab (eBioscience, San Diego, CA), pDC Ag (PDCA)-1 (eBioscience), Gr-1 Ab (eBioscience), CD3 Ab (eBioscience), CD11b Ab (BD Biosciences), CD19 Ab (Bio-Legend, San Diego, CA), sialic acid-binding Ig-like lectin (Siglec)-H Ab (BioLegend), CD11c Ab (BioLegend), rat IgG (BioLegend), or hamster IgG (BioLegend). Flow cytometric analysis was performed using an Accuri C6 flow cytometer (BD Biosciences) and CFlow Plus software (BD Biosciences).
Serum cytokine assay
Serum was subjected to separate ELISAs for a murine cytokine Ab array, IFN-a, IFN-b, BAFF (R&D Systems), and dsDNA Ab titer (Shibayagi Co., Gunma, Japan). Serum levels of anti-lactoferrin (LF) Ab titer were measured as previously described (26) .
Histology and immunohistochemistry
H&E staining was performed on paraffin-embedded pancreas samples. Histopathological evaluation of pancreatic lesions was performed to assess the degree of inflammatory cell infiltration (22, 23, 27) . Inflammatory infiltrates were scored as follows: 0, pancreas without mononuclear cell infiltration; 1, mononuclear cell aggregation and/or infiltration within the interstitium, with no parenchymal destruction; 2, focal parenchymal destruction with mononuclear cell infiltration; 3, diffuse parenchymal destruction but some intact parenchymal residue retained; and 4, almost all pancreatic tissue, except the pancreatic islets, destroyed or replaced with fibrosis or adipose tissue (22) . Immunofluorescence staining was performed using anti-amylase (Sigma-Aldrich), anti-PDCA-1 (BioLegend), and antimyeloperoxidase (MPO; Abcam, Eugene, OR) Abs followed by the incubation with matched secondary Abs (anti-rabbit or rat IgG-Alexa Fluor 488/ 546; Life Technologies, Carlsbad, CA) (28) . Depletion of pDCs was confirmed by the immunohistochemical analysis by using anti-PDCA-1 Ab (BioLegend) or anti-Siglec H Ab (Abcam). In some analyses, dsDNA in NETs and nuclei were stained with Sytox Orange (Life Technologies) (28, 29) .
Patient characteristics
We enrolled patients who were recently diagnosed with IgG4-RD and exhibited clinical features of AIP at Kyoto University Hospital and Kansai Medical University Hospital between January 2007 and September 2013. All human protocols were in compliance with the Declaration of Helsinki and approved by Kyoto University ethics committee. Written informed consent wasobtainedfromeachpatient.Twentypatientswereincluded(16malesand4 females; age range, 42-83 y; median, 68 y). Resected pancreas samples were obtained from 4 patients, peripheral blood cell samples were obtained from 13 patients, and serum samples were obtained from 15 patients. All patients were diagnosed with IgG4-related AIP according to the Japanese diagnostic criteria (30) . Patient serum IgG4 levels were much higher (range 226-1490 mg/dl; median 528.5 mg/dl) than the upper normal limit (135 mg/dl). In addition to healthy control samples, serum samples from patients with alcoholic chronic pancreatitis (n = 10) were also evaluated (all males; age range, 49-73 y; median 67 y).
Evaluation of serum IFN-a, BAFF, NETs, and anti-LF Ab titer
Serum samples from patients with IgG4-related AIP before therapeutic intervention (n = 11), healthy controls (n = 10), and patients with chronic pancreatitis (n = 10) were subjected to ELISA for measuring IFN-a (R&D Systems) and BAFF (Antigenix America, Huntington Station, NY). Serum NETs was quantified from the same samples using the Quant-iT PicoGreen dsDNA Reagent (Life Technologies) (28) . Serum anti-LFAb levels were also measured by ELISA (n = 15) (26).
Immunofluorescence staining of human pancreas samples
Paraffin-embedded pancreas tissue samples resected from patients with IgG4related AIP (n = 4), patients with pancreatic cancer (as controls; sections were free of tumor invasion as confirmed by H&E; n = 8), and patients with alcoholic chronic pancreatitis (n = 9) were prepared. Immunofluorescence staining was performed using anti-CD123 (Miltenyi Biotec, Auburn, CA), anti-CD303 (blood DC Ag 2 [BDCA2]; Miltenyi Biotec), anti-IgG4 (Southern Biotechnology Associates, Birmingham, AL), anti-IFN-a (Miltenyi Biotec), anti-BAFF (R&D Systems), and anti-MPO (Abcam) Abs, followed by incubation with matched secondary Abs (anti-mouse/rabbit IgG-Alexa Fluor 488/546; Life Technologies) (28) . In some analyses, dsDNA in NETs and nuclei were stained with Sytox Orange (Life Technologies) (28, 29) .
Observation and measurement of NET formation
Human neutrophils (2 3 10 7 /ml) were isolated from peripheral blood, and NET formation was visualized after stimulation with monosodium urate (MSU) crystals (InvivoGen; 50 mg/ml), rabbit anti-human LF IgG Ab (10 mg/ml; Sigma-Aldrich), or control rabbit IgG (10 mg/ml; Sigma-Aldrich). Quantitative analysis was performed by counting the number of NET-forming neutrophils per field under confocal laser scanning fluorescence microscopy (data are the mean from five randomly selected fields) (29) .
In vitro coculture and evaluation of cytokines and Igs in culture supernatants
Neutrophils were isolated from the peripheral blood of healthy controls and patients with IgG4-related AIP. CD19-positive B cells and pDCs were isolated from PBMCs using CD19 and CD303 (BDCA2) MicroBeads (Miltenyi Biotec), respectively. The purity of pDCs was .90% as assessed by flow cytometric analysis (data not shown). Neutrophils (1 3 10 6 /ml) were incubated with MSU crystals (50 mg/ml) or rabbit anti-LF IgG Ab (10 mg/ml; Sigma-Aldrich) for 3 h. Purified B cells (1 3 10 6 /ml) and pDCs (1 3 10 6 /ml) were added to the wells and incubated for 7 d. In some experiments, DNase (3 U/ml; Sigma-Aldrich), anti-IFNAR Ab (1 mg/ml; PBL Biomedical Laboratories, Piscataway, NJ), or control IgG (1 mg/ml; Sigma-Aldrich) was added to the coculture. Culture supernatants were collected and subjected to ELISAs for measuring IFN-a, BAFF, and IgG1, IgG4, or IgA (16, 17) .
Statistical analyses
For statistical analyses, t tests were performed using GraphPad Prism (GraphPad Software, La Jolla, CA). Differences with p , 0.05 were considered statistically significant.
Results
Type I IFN production and pDC infiltration characterize the pancreatitis induced by poly (I:C) in MRL /Mp mice, a model of AIP
In our initial studies, we used a well-established animal model of human AIP to identify the type of immune cells and cytokines that might be involved in the development of human AIP (27, 31) . Consistent with previous reports (27, 31) , MRL/Mp mice treated with poly (I:C) exhibited several important histological features of pancreatitis that were similar to human AIP. Thus, after treatment with poly (I:C), the pancreatic tissue of MRL/Mp mice exhibited a massive infiltration of immune cells, destruction of the pancreatic acinar architecture, and pancreatic fibrosis ( Fig. 1A) ; consistent with these changes, treated mice exhibited significantly higher pancreatitis inflammatory scores than untreated mice ( Fig. 1A ). In addition, treated mice exhibited a marked elevation in serum autoantibody levels, including anti-dsDNA Ab and anti-LF Ab (Fig. 1B ). Accompanying flow cytometric analysis revealed that treated mice as compared with untreated mice had a marked increase in the number of intrapancreatic CD3 + T cells, B220 + B cells, Gr-1 + neutrophils, and CD11b + macrophages (Fig. 1C) .
In further studies, we evaluated the cytokines and chemokines produced in mice with murine AIP. For this purpose, we analyzed serum or pancreatic lysates obtained from MRL/Mp mice with or without poly (I:C) treatment with cytokine and chemokine arrays. This analysis showed, as expected, that serum levels of prototypical proinflammatory cytokines such as TNF-a, IFN-g, and IL-6 were elevated in mice treated with poly (I:C). More interestingly, this analysis also showed that poly (I:C) injection was accompanied by a marked increase in a group of five chemokines, CXCL9, CXCL10, CXCL11, CCL2, and CCL5 in both serum and pancreatic lysates that are tightly regulated by type I IFNs ( Fig. 1D) (25, 32) . These findings prompted us to measure IFN-a and IFN-b serum levels in mice treated with poly (I:C), and indeed, we found that poly (I:C) injection led to a marked elevation of IFN-a and IFN-b serum levels (Fig. 1E ). These elevations also relate to the fact that serum levels of BAFF, a cytokine induced by type I IFN and considered to be involved in the immunopathogenesis of human IgG4-related AIP (16, 17) , were also elevated upon injection of mice with poly (I:C).
We reasoned that pDCs in the inflamed pancreas of poly (I:C)treated mice might be the source of the increased type I IFN production in these mice because pDCs are known to produce high levels of this cytokine (20) . To examine this possibility, we conducted flow cytometric analysis of pancreatic infiltrates derived from treated and untreated mice and indeed found that pDCs, defined as B220 dim PDCA-1 + cells (33, 34) , were significantly increased in the pancreatic infiltrate of mice treated with poly (I:C) ( Fig. 1F , left and middle panels). Consistent with previous reports regarding the cell-surface markers of pDCs (35, 36) , triple-color stainings revealed that pancreatic B220 dim PDCA-1 + pDCs were positive for both Siglec-H and CD11c and negative for CD19 (Supplemental Fig. 1 ). In addition, accompanying immunofluorescence analysis of pancreatic tissue from treated and untreated mice revealed increased accumulation of PDCA-1 + pDCs in the pancreas of the treated mice ( Fig. 1F , right panel). These findings led us to conclude that pDCs are greatly increased in the inflamed pancreas of mice treated with poly (I:C). In addition, as shown by pDC depletion studies described below, these pDCs are the major source of the greatly increased type I IFN produced by these treated mice.
Finally, we turned our attention to the possible mechanism of pDC stimulation in the inflamed pancreas of poly (I:C)-treated mice. Whereas poly (I:C) stimulation of pathogen recognition receptors in pDCs is likely to be one source of stimulation at least initially, two recent studies addressing the pathogenic roles of pDCs in SLE have provided evidence that neutrophil-associated NETs containing self-DNA as well as neutrophil-derived proteins are potent inducers of IFN-a production of pDC that is then involved in autoantibody production (37, 38) . Based on these studies, plus the facts that the pancreatitis in MRL/Mp mice treated with poly (I:C) contains Gr-1 + neutrophils and that serum Ab titer against LF, prototypical NET component (39) , was elevated, we determined if NETs are present in the inflamed pancreatic tissue. In fact, we found that NETs as defined by colocalization of extracellular dsDNA and MPO were present in the pancreatic tissue of mice treated with poly (I:C), but not in control mice (Fig. 1G ). These data thus suggest the possibility that pDCs producing IFN-a in the pancreas of MRL/Mp mice are being stimulated by NETs. Of interest, in the studies mentioned above (37, 38) , type I IFN is an inducer of NETs so that the latter is part of a positive-feedback loop that is both involved in type I IFN induction and is itself induced by type I IFN.
Depletion of pDCs prevents AIP in MRL /Mp mice
ThepresenceofpDCsandtypeIIFNinexperimentalAIPinMRL/Mp mice documented above led us to evaluate the role of these components in development of the AIP. To address this question, we determined the effect of multiple injections of 120G8 Ab, an Ab that has previously been shown to deplete pDCs (40), on AIP development. We found that repeated injections of 120G8 Ab were in fact effective in greatly reducing the number and percentages of pDCs in the pancreas of MRL/Mp mice as compared with mice treated with control Ab ( Fig. 2A ). The depletion of pDCs was further confirmed by the tissue-staining studies in which treatment with 120G8 Ab markedly reduced pancreatic infiltration of PDCA-1 + or Siglec-H + cells (Supplemental Fig. 2 ). In addition, such depletion of pDCs prevented AIP development as assessed by pathological analysis (Fig. 2B ) and reductions in the numbers of infiltrating T cells, B cells, and CD11b + macrophages in the pancreas (Fig. 2C ). Perhaps more importantly, depletion of pDCs led to a marked decrease in systemic type I IFN-related responses, as assessed by greatly diminished production of IFN-a and BAFF (Fig. 2D ). In addition, such depletion caused greatly reduced pancreatic NETs formation ( Fig.  2E ) as well as a significant reduction in serum Ab titers against LF, a prototypical NET component (Fig. 2F ). These data thus suggested that pDCs play a critical role in the pathogenesis of AIP in MRL/Mp mice treated with poly (I:C).
IFN-a-mediated signaling pathway blockade prevents AIP in MRL /Mp mice
The pDC depletion studies above showed that depletion resulted in a significant reduction of type I IFN production in mice with ex-perimentalAIPbutdidnotdeterminehowsuchreductionoftypeIIFN led to reduced pancreatitis. To answer this question, we determined the effect of treating mice with neutralizing Ab against IFNAR (24) on the development of experimental AIP.
The Journal of Immunology We found that such treatment of MRL/Mp mice inhibited AIP development to about the same extent as pDC depletion ( Fig. 3A) and coincided with the fact that the number of pDCs in the pancreas was also significantly reduced, indicating that type I IFN production is involved in the pancreatic accumulation of pDCs ( Fig. 3B ). Consistent with this reduction in the number of pancreatic pDCs, serum levels of IFN-a and BAFF were significantly reduced in mice treated with the anti-IFNAR Ab, as was the case with mice treated with pDC-depleting Ab (Fig. 3C ). Moreover, pancreatic NET formation and elevation of the serum anti-LF Ab titer was inhibited in mice treated with anti-IFNAR Ab (Fig. 3D ). These data have several implications. First, they show that production of type I IFN (particularly IFN-a) is a critical factor in the development of experimental murine AIP. Second, they show that type I IFN production is required for the maintenance of the increased pancreatic infiltration of pDCs necessary for AIP development. The most likely explanation for this latter effect is that type I IFN is also necessary for NET generation, a possible activator of pDCs.
Pancreatic infiltration of IFN-a producing pDCs in patients with IgG4-related AIP
The studies of experimental AIP in MRL/Mp mice discussed above allowed us to probe the mechanism of human IgG4-related AIP; in particular, they allowed us to determine the relevance of pDCmediated IFN-a signaling pathways in this disease.
In initial studies, we measured IFN-a levels in the serum of patients with IgG4-related AIP and control individuals. Serum IFN-a levels were markedly elevated in patients with IgG4-related AIP as compared with healthy controls or patients with chronic pancreatitis (Fig. 4A ). Consistent with previous reports (41, 42) , this elevation correlated with elevated serum BAFF levels (Fig. 4A ).
We next conducted immunohistochemical studies of pancreatic tissue from patients with IgG4-related AIP who had undergone pancreatectomy (n = 4) as well as control pancreatic tissue from patients with pancreatic cancer (noncancerous tissue) (n = 8) and with alcoholic chronic pancreatitis (n = 9) to determine levels of pancreatic pDC infiltration in these diseases. The pancreatic tissues of patients with IgG4-related AIP were distinguished from the control tissues by the fact that they displayed storiform fibrosis (Fig. 4B, left panel) as well as a massive infiltration of inflammatory cells enriched in IgG4 + plasma cells (Fig. 4B, right panel) . These characteristics were in line with the published Japanese criteria for the diagnosis of IgG4-related AIP (30) . More importantly, the pancreatic tissues from patients with IgG4-related AIP, but not control pancreas tissues or chronic pancreatitis tissues, contained easily identified cells bearing CD123 and BDCA2, both of which are established markers of human pDCs (43) (Fig. 4C, Supplemental  Fig. 3 ). In addition, the pancreatic BDCA2 + pDCs from patients with IgG4-related AIP expressed both IFN-a and BAFF (Fig. 4D) . These data suggest that pDCs are a major component of the pancreatic lesion in patients with IgG4-related AIP; in addition, because these cells express IFN-a, it is likely that pDC-derived IFN-a responses are one of the prominent features of IgG4-related AIP, as is the case in the murine AIP model described above.
NET formation in patients with IgG4-related AIP
Having confirmed that pDCs producing IFN-a are present in the inflamed pancreas of both experimental AIP and human IgG4related AIP, we hypothesized that AIP in humans was similar to Representative images by H&E staining are shown in the left panel. The pancreatic pathology of MRL/Mp mice treated with anti-IFNAR Ab or control Ab was evaluated as described in Fig. 1 (right panel). (B) Representative dot plots of flow cytometric analyses for the detection of pDCs (left panel). The number of pDCs in the pancreas was determined as described in Fig. 1 (right panel) . (C) Serum levels of IFN-a, IFN-b, and BAFF in mice treated with anti-IFNAR Ab and control Ab. (D) Immunofluorescent detection of NETs visualized by extracellular colocalization of MPO and dsDNA. NET formation is indicated by white arrows. Serum levels of anti-LF Ab titer were determined as described in Fig. 1 (arbitrary units [a. u.]). Results are expressed as the mean 6 SE. *p , 0.05, **p , 0.01. that in mice in that NET formation in the pancreas also contributes to pDC activation and subsequent IFN-a production.
To examine this possibility, we initially performed immunohistochemical studies to determinewhether NET formation occurs in the inflamed pancreas of IgG4-related AIP patients. To this end, we stained pancreatic tissue to identify both extracellular MPO and dsDNA using a method similar to that employed in the detection of NETs in the inflamed pancreas of MRL/Mp mice treated with poly (I: C). We found that pancreatic tissue from patients with IgG4-related AIP does contain extracellular NET structures characterized by dsDNA colocalized with MPO, whereas pancreatic tissues from controls and patients with chronic pancreatitis did not contain these structures (Fig. 5A) . Serum NET concentrations, as determined by measuring serum dsDNA, were also higher in patients with IgG4related AIP than in either healthy controls or patients with chronic pancreatitis, albeit with borderline significance (Fig. 5B) . These data suggest that NET formation is in fact induced in pancreatic lesions of patients with IgG4-related AIP.
Recent studies have shown that neutrophils can be stimulated to produce NETs by immune complexes composed of proteins released by the neutrophils and autoantibodies recognizing these proteins or simply by the autoantibodies alone if they recognize neutrophil surface Ags (44) . In addition, Okazaki et al. (26) have reported that Ab titers against LF, a NET component protein, were elevated in patients with AIP as well as in the mice with experimental AIP described above. With this information in hand, we next considered the possibility that NET formation in IgG4-related AIP pancreatic tissue is induced, at least in part, by LF-anti-LFAb immune complexes. We found first that the serum anti-LF Ab titer was increased in the serum of patients with IgG4-related AIP and that this increase was especially prominent in Abs of the IgG4 subclass (i.e., the IgG subclass associated with this disease) (Fig. 5C ). We then found that exposure of neutrophils from normal individuals to polyclonal anti-human LF Ab induced the formation of NETs to the same extent as exposure to MSU crystals, a well-established NET inducer (Fig. 5D, 5E ). Thus, it seemed likely that NET formation in IgG4-related AIP pancreatic tissue is due, in part, to release of LF and the formation of LF-anti-LF Ab immune complexes (38, 45 ) (see further discussion below).
IgG4 production by NET-stimulated pDC
Having established that neutrophils in pancreatic lesions of patients with IgG4-related AIP produce NETs as well as the potential relation between such NET formation and patient anti-LF Ab production, we next turned our attention to the role of NETs in pDC function. In initial studies along these lines, we determined the capacity of peripheral blood CD19 + B cells from healthy control individuals to produce IgG4 when cocultured with neutrophils and/ or pDCs in the presence or absence of NETs induced by the addition of MSU crystals to the culture. The results showed that in the presence of MSU-induced NETs and pDCs, healthy control B cells produced significantly greater amounts of IgG4 (but not IgG1 or IgA) than when cultured with pDCs alone (Fig. 6A ). This enhanced IgG4 B cell response was accompanied by a marked increase in both IFN-a and BAFF production (Fig. 6B) . The latter were likely due to NET-induced IFN-a production, because the increases were blocked by DNase inhibition of NET formation or by neutralization of IFN-a-mediated signaling pathways by anti-IFNAR Ab (Fig. 6C ). In addition, the NETs themselves were not directly involved in IgG4 production because addition of IFN-a or BAFF to cultures of B cells from control individuals in the absence of NETs or pDCs also led to enhanced IgG4 production (data not shown).
Very similar results were obtained with cocultures in which NETs were induced by a polyclonal anti-LF IgG Ab instead of MSU in the absence of the addition of exogenous LF (Fig. 6D, 6E ). Presumably the latter can occur because, as shown previously, the neutrophils are capable of producing LF that can then react with anti-LF Ab to form NET-stimulating immune complexes (46, 47) . It should be noted, however, that IgG4 subclass isolated from patient serum did not have the capacity to induce NETs in vitro, probably because the concentration of anti-LF Ab in this preparation was too low (data not shown).
Taken together, these coculture studies provide evidence that NETs induced by MSU or anti-LFAb lead to IgG4 Ab production by control B cells through a pDC IFN-a-mediated signaling pathway. It should be noted that such IFN-a/BAFF mediated IgG4 production could be due to either expansion of a pre-existing IgG4 B cell subset or to selective IgG4 class-switch differentiation plus expansion.
pDC activation by NETs plays an essential role in IgG4 generation
Although the above coculture studies using healthy control samples identified the important role of the neutrophil-pDC interaction in IgG4 production, they did not specifically address the contributions of the patient and control neutrophils or pDCs to such production.
To answer this question, we evaluated IgG4 production in cocultures containing neutrophils, pDCs, and B cells from both controls and patients with IgG4-related AIP invarious combinations. The results indicated that IgG4 production by control B cells was markedly enhanced by cocultures containing pDCs from patients with IgG4-related AIP in the presence of MSU-induced NETs as compared with cultures containing pDCs from control individuals, regardless of the source of the NET-producing neutrophils (Fig.  7A ). In addition, IFN-a and BAFF production were also markedly FIGURE 6. Enhanced IgG4 production by pDCs in response to NETs. (A and B) Ig production by B cells cocultured with NET-activated pDCs. Neutrophils (Neut), pDCs, and B cells were isolated from the peripheral blood of healthy controls (n = 6). Neutrophils (1 3 10 6 /ml) were incubated with MSU crystals for 3 h to induce NET formation, after which pDCs (1 3 10 6 /ml) and B cells (1 3 10 6 /ml) were added to the coculture for 7 d and Ig production in the culture supernatants was measured (A). IFN-a and BAFF production in the culture supernatants was measured by ELISA (B). (C) Inhibition of IgG4 production by an anti-IFN-ab receptor (IFNAR) Ab (1 mg/ml) and DNase (3 U/ml) in the coculture composed of MSU-induced NETs, pDCs, and B cells from healthy controls (n = 6). Production of IgG4, IFN-a, and BAFF in culture supernatants was measured by ELISA. Production of IgG4 or cytokines in the presence of control Ab and the absence of anti-IFNAR Ab or DNase was defined as 100% in each sample. (D and E) Ig production by B cells cocultured with pDCs activated by NETs, which were induced by an anti-LF Ab. (D) Neutrophils were incubated with anti-LF Ab (10 mg/ml) or MSU (50 mg/ml) for 3 h to induce NET formation, after which pDCs and B cells were added as described in (A). (E) Neutrophils were incubated with anti-LFAb or MSU for 3 h to induce NET formation, after which pDCs and B cells were added in the presence of anti-IFNAR Ab and DNase for 7 d (n = 4). IgG4 and IFN-a production was measured in culture supernatants. Production of IgG4 or cytokines in the presence of control Ab and the absence of anti-IFNAR Ab or DNase was defined as 100% in each sample. Results are expressed as the mean 6 SE. *p , 0.05, **p , 0.01. elevated in supernatants from cocultures containing pDCs from patients with IgG4-related AIP, but not those containing pDCs from control individuals (Fig. 7A) .
Consistent with the fact that control and patient neutrophils had an equal capacity to support IgG4 production in the coculture system, neutrophils isolated from healthy controls and patients with IgG4related AIP exhibited equivalent amounts of NET formation upon exposure to MSU crystals (Fig. 7B ). In addition, inhibition of NET formation by DNase or blockade of IFN-a-mediated signaling pathways by anti-IFNAR Ab significantly reduced IgG4 production in a coculture system comprised of control B cells, patient-derived neutrophils, and patient-derived pDCs (Fig. 7C) . Finally, IgG4 production by control B cells was also enhanced in the presence of NETs induced by anti-LF Ab when the cells were cocultured with pDCs from patients with IgG4-related AIP (Fig. 7D) , and this enhancement was again inhibited by the addition of DNase or by anti-IFNAR Ab (Fig. 7E ). Taken together, these data suggest that pDCs, rather than neutrophils, have an indispensable role in the generation of IgG4 responses by B cells in patients with IgG4-related AIP and that NET-triggered pDC activation followed by IFN-a production is required for the development of IgG4-related AIP.
Discussion
The immunologic mechanisms underlying the pathogenesis of IgG4-RD as well as the increased production of the IgG4 subclass that characterizes this inflammatory disease are still poorly defined. In this study,weaddressthisquestionwithstudiesofmicewithexperimental AIP, MRL/Mp mice treated with poly (I:C), and studies of patients with IgG4-related AIP. The studies of the treated MRL/Mp mice showed that experimental AIP is characterized by a chronically inflamed pancreas exhibiting destruction of acinar architecture, massive infiltration of immune cells, and fibrosis; all findings were shared by human AIP. Although the pathogenic roles of proinflammatory cytokines such as IFN-g, IL-6, and TNF-a are implicated in the development of such experimental AIP (31, 48) , the roles of type I IFNs in this model had been poorly defined. In this study, we showed that experimental AIP is associated with the pancreatic infiltration of pDCs that have either migrated to or have Fig. 6A . Neutrophils isolated from healthy controls (Ctrl; n = 6) or patients with IgG4-related AIP (Pt; n = 8) were subjected to NET induction by MSU as described in Fig. 6 . pDCs isolated from healthy controls (Ctrl) or patients with IgG4-related AIP (Pt) were subjected to the coculture assay together with B cells isolated from healthy controls (Ctrl B). IgG4, IFN-a, and BAFF production in the coculture supernatant was determined by ELISA. (B) Neutrophils (Neut) isolated from healthy controls (Ctrl; n = 5) and patients with IgG4-related AIP (Pt; n = 5) were subjected to NET induction by MSU, as described in Fig. 5 . NET formation was determined by counting the number of NET-forming cells under high-power field. (C) Inhibition of IgG4 production by the addition of an anti-IFN-ab receptor Ab (IFNAR Ab) and DNase. B cells from healthy controls (Ctrl B; n = 6) were cocultured with pDCs (Pt pDCs) and MSU-induced NETs (Pt Neut) derived from patients with IgG4-related AIP (n = 6) in the presence of anti-IFNAR Ab or DNase for 7 d, as described in Fig. 6C . Production of IgG4 or cytokines in the presence of control Ab and absence of anti-IFNAR Ab or DNase was defined as 100% in each sample. (D and E) Ig production by healthy control B cells (Ctrl B) cocultured with pDCs from patients with IgG4-related AIP (Pt pDCs) activated by NETs, which were induced by an anti-LF Ab. IgG4-related AIP patient-derived neutrophils (Pt Neut) were incubated with anti-LF Ab (10 mg/ml) or MSU (50 mg/ml) for 3 h to induce NET formation, after which Pt pDCs and Ctrl B cells were added (D). Pt Neut were incubated with anti-LF Ab for 3 h to induce NET formation, after which Pt pDCs and Ctrl B cells were added in the presence of the anti-IFNAR Ab and DNase for 7 d (n = 4) (E). IgG4 and IFN-a production in culture supernatants were measured as described in Fig. 6 . Production of IgG4 or cytokines in the presence of control Ab and absence of anti-IFNAR Ab or DNase was defined as 100% in each sample. Results are expressed as the mean 6 SE. *p , 0.05, **p , 0.01. been expanded in this organ; these cells are the likely source of a markedly increased production of IFN-a. We confirmed the importance of this pDC-mediated IFN-a production to the development of the pancreatic inflammation by showing that systemic administration of pDC-depleting Ab (120G8 Ab) and neutralizing Ab against IFNAR led to almost complete amelioration of disease.
In parallel with the murine AIP findings, studies of IgG4-related AIP disclosed that human AIP was also associated with pDCs localized in the pancreas producing IFN-a. Whether or not such production is a major driver of the human pancreatic inflammation as in the mouse model is still not established and awaits the outcome of clinical trials with anti-IFN-a Ab or anti-IFNAR Ab. In any case, we could show that patient-derived peripheral blood pDCs enhanced IgG4 Ab production by B cells through an IFN-a-mediated signaling mechanism. Thus, a central feature of both experimental murine AIP and human IgG4-related AIP pathogenesis is the activation of pDCs producing IFN-a, and in the case of the human disease, this pDC abnormality is a factor in the excessive IgG4 production that characterizes this disease.
Our studies of both the murine model of AIP and patients with IgG4-related AIP disclosed that the inflamed pancreas harbored NETs (i.e., weblike structures composed of chromatin, molecules derived from granules, and some cytoplasmic proteins that are generated by stimulated and dying neutrophils) (21) . In addition, the titer of autoantibody against LF, a NET component protein, is markedly elevated in the serum of mice with murine experimental AIP and patients with IgG4-related AIP. These structures in other studies have been shown to be involved in pDC activation (34, 38) and were therefore assumed to have a similar role in AIP. In the case of human IgG4-related AIP, the role of NETs in activation of pDCs was actively studied using pDCs isolated from the circulation as well as NETs generated in vitro with either MSU or anti-LFAb. In support of the hypothesis that NETs are stimulators of pDC production of IFN-a, we found that cocultures of pDCs with neutrophils induced to express NETs by either MSU or anti-LF Ab lead to stimulation of pDC production of IFN-a and BAFF as well as the induction of IgG4 production by normal B cells also present in the coculture. Thus, assuming that the induced NETs in the culture mimic those in the pancreas, these in vitro data offer convincing evidence that NET structures are in fact an important stimulatory component in the pancreas in both murine and human AIP. However, it is also possible that other signaling mechanisms are also present, such as direct stimulation of pDCs by TLR7 and TLR9 ligands associated with commensal flora that have gained access to the inflamed pancreas. Finally, it should also be noted that pDCs in patients with IgG4related AIP have other as-yet-undisclosed abnormalities that render them more susceptible to NET activation than normal pDCs.
Although in the current study, we showed that MSU and anti-LF Ab were capable of initiating IFN-a production by pDCs, it is not clear that these stimulants are actually those that are operative in the induction of this cytokine in patients with IgG4-related AIP. The deposition of MSU into appendicular joints has an essential role in the development of acute gout (49) , and recent studies have provided evidence that MSU-induced NETs initiate inflammatory responses in this disease (50, 51) . Whether a similar mechanism is applied to IgG4-related AIP requires further studies to demonstrate that MSU deposition occurs in IgG4-related pancreatic lesions as well as evaluation of whether uric acid-clearing agents have efficacy in patients with IgG4-related AIP. The relevance of anti-LFAb to IFN-a production in IgG4-related AIP is somewhat more likely than MSU, because serum anti-LF Ab titers were elevated in the serum of patients with IgG4-RD and experimental AIP. However, these data may merely indicate that neutrophil function as a general source of autoantigens in IgG4-related AIP, and any of several of these autoantigens can trigger the formation of immune complexes that stimulate NET formation. In this regard, we speculate that neutrophil release of autoantigens and subsequent formation of immune complexes comprise a positive-feedback loop that favors NET induction, ultimately leading to the release of NET Ags with the capacity to stimulate pDCs to produce IFN-a. However, confirmation of this idea requires future studies that evaluate serum Ab profiles against various types of NET proteins in IgG4-related AIP; in addition, studies that evaluate whether immune complexes, including LF-anti-LF Ab immune complexes, can stimulate pDCs independently of NETs are also needed.
Our coculture experiments using neutrophils and pDCs from healthy controls and patients with IgG4-related AIP incubated together in various combinations clearly showed that pDCs, rather than neutrophils, were indispensable for the generation of IgG4 responses in patients with IgG4-related AIP. In most instances, pDCs serve important host-defense functions, particularly in relation to viral infection (20) . This protection is accomplished by their ability to sense microbial nucleic acids by TLR7 and TLR9 and then produce IFN-a, a cytokine that leads to adaptive generation of Th1 and Th17 responses (20, 52) . However, evidence has recently been obtained that such IFN-a production could also be involved in initiation of various diseases. In particular, excessive IFN-a production by pDCs in response to self-DNA has been implicated in the pathogenesis of autoimmune diseases such as psoriasis and SLE (20, 53) . In the case of SLE, such IFN-a production is considered to arise from NET release of autoimmune complexes that activate pDCs in the same way suggested in this study to occur in IgG4-related AIP. However, despite these mechanistic similarities, the clinicopathological features of these two diseases are completely different. In particular, enhancement of IgG4 Ab responses and storiform fibrosis formation are observed in IgG4-related AIP and not in SLE, whereas widespread organ and tissue damage from autoantibody deposition is seen in SLE but not in IgG4-related AIP. This discrepancy can be partially explained by the presence of a significant population of patients with SLE having autoantibodies against BAFF that partially blunt certain autoimmune responses including IgG4 production (54) . In addition, there is likely to be a difference between SLE and IgG4-related AIP in Treg responses. Thus, whereas Treg responses are increased in IgG4-related AIP (13, 14) , they are defective in SLE (55, 56) . Given that pDCs have been shown to induce and support Treg function (53, 57) , we assume that pDC activation in IgG4related AIP is accompanied by the induction of Treg-derived cytokines that limit the production of destructive autoantibodies.
We previously showed that TLR and nucleotide-binding oligomerization domain-like receptor activation of monocytes and basophils isolated from patients with IgG4-related AIP enhance IgG4 production by B cells from healthy controls (16, 17) . This correlated with evidence that monocytes and basophils activated by MAMPs could be involved in the development of IgG4-related AIP. In the current study, we identified another type of innate immune response mediated by neutrophils and pDCs in the development of IgG4-related AIP. Distinct from the MAMP-activated pathways mentioned above, this pathway is triggered by the activation of neutrophils by endogenous danger signals, such as damage-associated molecular patterns (MSU crystals) and autoantibodies (anti-LF Ab). At the moment, it is not clear if these pathways are largely separate and thus that responses to either microbial Ags or endogenous factors can trigger the abnormal innate immune response leading to IgG4-related AIP or, alternately, these pathways are interrelated. The latter possibility is suggested by the fact that both pathways result in enhancement of BAFF production by innate cells and the subsequent production of IgG4 by B cells (16, 17) . Clinical observations showing that serum BAFF levels are significantly higher in patients with IgG4-related AIP than in normal individuals (41, 42) support the importance of this cytokine in the immunopathogenesis of this disease.
In conclusion, our findings show that both murine AIP and human IgG4-related AIP are characterized by greatly increased pDC activation and IFN-a production and that, in the case of the murine disease, this could be shown to be a critical mechanism underlying the pancreatic inflammation. In addition, both the murine and human AIP were associated with the presence of pancreatic NETs, neutrophil-derived structures that in the case of the human disease were shown with in vitro studies of induced NETs to be a cause of pDC activation as well as increased IFN-a and BAFF production. Finally, this NET-induced IFN-a and BAFF production by pDCs was shown to be responsible, at least in part, for B cell production of the signature abnormality of this form of autoimmunity in humans, IgG4-RD.
